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Prevention and Control of Influenza:
Part I, Vaccines
Recommendations of the Advisory Committee on
Immunization Practices (ACIP)
Summary
These recommendations update information on the vaccine available for con-
trolling influenza during the 1994–95 influenza season. The recommendations
supersede MMWR 1993;42(No. RR-6)1–13.
Antiviral agents also have an important role in the control of influenza. Rec-
ommendations for the use of antiviral agents will be published later in 1994 as
Part II of these recommendations.
INTRODUCTION
Influenza A viruses are classified into subtypes on the basis of two surface anti-
gens: hemagglutinin (H) and neuraminidase (N). Three subtypes of hemagglutinin
(H1, H2, and H3) and two subtypes of neuraminidase (N1 and N2) are recognized
among influenza A viruses that have caused widespread human disease. Immunity to
these antigens—especially to the hemagglutinin—reduces the likelihood of infection
and lessens the severity of disease if infection occurs. Infection with a virus of one
subtype confers little or no protection against viruses of other subtypes. Furthermore,
over time, antigenic variation (antigenic drift) within a subtype may be so marked that
infection or vaccination with one strain may not induce immunity to distantly related
strains of the same subtype. Although influenza B viruses have shown more antigenic
stability than influenza A viruses, antigenic variation does occur. For these reasons,
major epidemics of respiratory disease caused by new variants of influenza continue
to occur. The antigenic characteristics of circulating strains provide the basis for se-
lecting the virus strains included in each year’s vaccine.
Typical influenza illness is characterized by abrupt onset of fever, myalgia, sore
throat, and nonproductive cough. Unlike other common respiratory illnesses, influ-
enza can cause severe malaise lasting several days. More severe illness can result if
either primary influenza pneumonia or secondary bacterial pneumonia occurs. During
influenza epidemics, high attack rates of acute illness result in both increased
numbers of visits to physicians’ offices, walk-in clinics, and emergency rooms and
increased hospitalizations for management of lower respiratory tract complications.
Elderly persons and persons with underlying health problems are at increased risk
for complications of influenza. If they become ill with influenza, such members of
high-risk groups (see Groups at Increased Risk for Influenza-Related Complications
under Target Groups for Special Vaccination Programs) are more likely than the gen-
eral population to require hospitalization. During major epidemics, hospitalization
rates for persons at high risk may increase two- to five-fold, depending on the
age group. Previously healthy children and younger adults may also require
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hospitalization for influenza-related complications, but the relative increase in their
hospitalization rates is less than for persons who belong to high-risk groups.
An increase in mortality further indicates the impact of influenza epidemics. In-
creased mortality results not only from influenza and pneumonia but also from
cardiopulmonary and other chronic diseases that can be exacerbated by influenza. It
is estimated that >10,000 influenza-associated deaths occurred during each of seven
different U.S. epidemics in the period 1977–1988, and >40,000 influenza-associated
deaths occurred during each of two of these epidemics. Approximately 90% of the
deaths attributed to pneumonia and influenza occurred among persons ≥65 years of
age.
Because the proportion of elderly persons in the U.S. population is increasing and
because age and its associated chronic diseases are risk factors for severe influenza
illness, the number of deaths from influenza can be expected to increase unless con-
trol measures are implemented more vigorously. The number of persons <65 years of
age at increased risk for influenza-related complications is also increasing. Better sur-
vival rates for organ-transplant recipients, the success of neonatal intensive-care
units, and better management of diseases such as cystic fibrosis and acquired immu-
nodeficiency syndrome (AIDS) result in a higher survival rate for younger persons at
high risk.
OPTIONS FOR THE CONTROL OF INFLUENZA
In the United States, two measures are available that can reduce the impact of
influenza: immunoprophylaxis with inactivated (killed-virus) vaccine and chemo-
prophylaxis or therapy with an influenza-specific antiviral drug (amantadine or riman-
tadine). Vaccination of persons at high risk each year before the influenza season is
currently the most effective measure for reducing the impact of influenza. Vaccination
can be highly cost effective when a) it is directed at persons who are most likely to
experience complications or who are at increased risk for exposure and b) it is admin-
istered to persons at high risk during hospitalizations or routine health-care visits
before the influenza season, thus making special visits to physicians’ offices or clinics
unnecessary. When vaccine and epidemic strains of virus are well matched, achieving
high vaccination rates among persons living in closed settings (e.g., nursing homes
and other chronic-care facilities) can reduce the risk for outbreaks by inducing herd
immunity.
INACTIVATED VACCINE FOR INFLUENZA A AND B
Each year’s influenza vaccine contains three virus strains (usually two type A and
one type B) representing the influenza viruses that are likely to circulate in the United
States in the upcoming winter. The vaccine is made from highly purified, egg-grown
viruses that have been made noninfectious (inactivated). Influenza vaccine rarely
causes systemic or febrile reactions. Whole-virus, subvirion, and purified-surface-
antigen preparations are available. To minimize febrile reactions, only subvirion or
purified-surface-antigen preparations should be used for children; any of the prepara-
tions may be used for adults.
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Most vaccinated children and young adults develop high postvaccination
hemagglutination-inhibition antibody titers. These antibody titers are protective
against illness caused by strains similar to those in the vaccine or the related variants
that may emerge during outbreak periods. Elderly persons and persons with certain
chronic diseases may develop lower postvaccination antibody titers than healthy
young adults and thus may remain susceptible to influenza-related upper respiratory
tract infection. However, even if such persons develop influenza illness despite vacci-
nation, the vaccine has been shown to be effective in preventing lower respiratory
tract involvement or other secondary complications, thereby reducing the risk for hos-
pitalization and death.
The effectiveness of influenza vaccine in preventing or attenuating illness varies,
depending primarily on the age and immunocompetence of the vaccine recipient and
the degree of similarity between the virus strains included in the vaccine and those
that circulate during the influenza season. When there is a good match between
vaccine and circulating viruses, influenza vaccine has been shown to prevent illness in
approximately 70% of healthy persons <65 years of age. In these circumstances, stud-
ies have also indicated that influenza vaccine is approximately 70% effective in
preventing hospitalization for pneumonia and influenza among elderly persons living
in settings other than nursing homes or similar chronic-care facilities.
Among elderly persons residing in nursing homes, influenza vaccine is most effec-
tive in preventing severe illness, secondary complications, and death. Studies of this
population have shown the vaccine to be 50%–60% effective in preventing hospitaliza-
tion and pneumonia and 80% effective in preventing death, even though efficacy in
preventing influenza illness may often be in the range of 30%–40% among the frail
elderly. Achieving a high rate of vaccination among nursing home residents has been
shown to reduce the spread of infection in a facility, thus preventing disease through
herd immunity.
RECOMMENDATIONS FOR USE OF INFLUENZA VACCINE
Influenza vaccine is strongly recommended for any person ≥6 months of age who—
because of age or underlying medical condition—is at increased risk for complications
of influenza. Health-care workers and others (including household members) in close
contact with persons in high-risk groups should also be vaccinated. In addition, influ-
enza vaccine may be administered to any person who wishes to reduce the chance of
becoming infected with influenza. The trivalent influenza vaccine prepared for the
1994–95 season will include A/Texas/36/91-like (H1N1), A/Shangdong/9/93-like (H3N2),
and B/Panama/45/90-like hemagglutinin antigens. Recommended doses are listed in
Table 1. Guidelines for the use of vaccine among different groups follow.
Although the current influenza vaccine can contain one or more of the antigens
administered in previous years, annual vaccination with the current vaccine is neces-
sary because immunity declines in the year following vaccination. Because the
1994–95 vaccine differs from the 1993–94 vaccine, supplies of 1993–94 vaccine should
not be administered to provide protection for the 1994–95 influenza season.
Two doses administered at least 1 month apart may be required for satisfactory
antibody responses among previously unvaccinated children <9 years of age; how-
ever, studies with vaccines similar to those in current use have shown little or no
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improvement in antibody responses when a second dose is administered to adults
during the same season.
During the past decade, data on influenza vaccine immunogenicity and side effects
have been obtained for intramuscularly administered vaccine. Because there has been
no adequate evaluation of recent influenza vaccines administered by other routes, the
intramuscular route is recommended. Adults and older children should be vaccinated
in the deltoid muscle and infants and young children in the anterolateral aspect of the
thigh.
TARGET GROUPS FOR SPECIAL VACCINATION PROGRAMS
To maximize protection of high-risk persons, they and their close contacts should
be targeted for organized vaccination programs.
Groups at Increased Risk for Influenza-Related Complications:
• Persons ≥65 years of age
• Residents of nursing homes and other chronic-care facilities that house persons of
any age with chronic medical conditions
• Adults and children with chronic disorders of the pulmonary or cardiovascular sys-
tems, including children with asthma
• Adults and children who have required regular medical follow-up or hospitalization
during the preceding year because of chronic metabolic diseases (including diabe-
tes mellitus), renal dysfunction, hemoglobinopathies, or immunosuppression
(including immunosuppression caused by medications)
• Children and teenagers (6 months–18 years of age) who are receiving long-term
aspirin therapy and therefore may be at risk for developing Reye syndrome after
influenza
TABLE 1. Influenza vaccine* dosage, by age group — United States, 1994–95 season
Age group Product† Dosage No. doses Routes§
6–35 mos Split virus only 0.25 mL 1 or 2¶ IM
3–8 yrs Split virus only 0.50 mL 1 or 2¶ IM
9–12 yrs Split virus only 0.50 mL 1 IM
 >12 yrs Whole or split virus 0.50 mL 1 IM
*Contains 15 µg each of A/Texas/36/91-like (H1N1), A/Shangdong/9/93-like (H3N2), and
B/Panama/45/90-like hemagglutinin antigens in each 0.5 mL. Manufacturers include: Connaught
Laboratories, Inc. (Fluzone whole or split); Evans Medical Ltd. (distributed by Adams Labo-
ratories, Inc.) (Fluviron purified surface antigen vaccine); Parke-Davis (Fluogen split); and
Wyeth-Ayerst Laboratories (Flushield split). For further product information call Connaught,
(800) 822-2463; Adams, (800) 932-1950; Parke-Davis, (800) 223-0432; Wyeth-Ayerst, (800) FLU-
SHIELD.
†Because of the lower potential for causing febrile reactions, only split-virus vaccines should
be used for children. They may be labeled as “split,” “subvirion,” or “purified-surface-antigen”
vaccine. Immunogenicity and side effects of split- and whole-virus vaccines are similar among
adults when vaccines are administered at the recommended dosage.
§The recommended site of vaccination is the deltoid muscle for adults and older children. The
preferred site for infants and young children is the anterolateral aspect of the thigh.
¶Two doses administered at least 1 month apart are recommended for children <9 years of age
who are receiving influenza vaccine for the first time.
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Groups that Can Transmit Influenza to Persons at High Risk
Persons who are clinically or subclinically infected and who care for or live with
members of high-risk groups can transmit influenza virus to them. Some persons at
high risk (e.g., the elderly, transplant recipients, and persons with AIDS) can have low
antibody responses to influenza vaccine. Efforts to protect these members of high-risk
groups against influenza may be improved by reducing the likelihood of influenza ex-
posure from their care givers. Therefore, the following groups should be vaccinated:
• Physicians, nurses, and other personnel in both hospital and outpatient-care
settings;
• Employees of nursing homes and chronic-care facilities who have contact with pa-
tients or residents;
• Providers of home care to persons at high risk (e.g., visiting nurses and volunteer
workers);
• Household members (including children) of persons in high-risk groups.
VACCINATION OF OTHER GROUPS
General Population
Physicians should administer influenza vaccine to any person who wishes to
reduce the likelihood of becoming ill with influenza. Persons who provide essential
community services may be considered for vaccination to minimize disruption of es-
sential activities during influenza outbreaks. Students or other persons in institutional
settings, such as those who reside in dormitories, should be encouraged to receive
vaccine to minimize the disruption of routine activities during epidemics.
Pregnant Women
Influenza-associated excess mortality among pregnant women has not been docu-
mented except in the pandemics of 1918–19 and 1957–58. However, pregnant women
who have other medical conditions that increase their risks for complications from
influenza should be vaccinated because the vaccine is considered safe for pregnant
women—regardless of the stage of pregnancy. Thus, it is undesirable to delay vacci-
nation of pregnant women who have high-risk conditions and who will still be in the
first trimester of pregnancy when the influenza season begins.
Persons Infected with Human Immunodeficiency Virus (HIV)
Limited information exists regarding the frequency and severity for influenza ill-
ness among HIV-infected persons, but reports suggest that symptoms may be
prolonged and the risk for complications increased for some HIV-infected persons.
Because influenza can result in serious illness and complications, vaccination is a pru-
dent precaution and will result in protective antibody levels in many recipients.
However, the antibody response to vaccine may be low in persons with advanced HIV-
related illnesses; a booster dose of vaccine does not improve the immune response
for these persons.
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Foreign Travelers
The risk for exposure to influenza during foreign travel varies, depending on sea-
son and destination. In the tropics, influenza can occur throughout the year; in the
southern hemisphere, the season of greatest activity is April–September. Because of
the short incubation period for influenza, exposure to the virus during travel can result
in clinical illness that begins while traveling, an inconvenience or potential danger,
especially for persons at increased risk for complications. Persons preparing to
travel to the tropics at any time of year or to the southern hemisphere during April–
September should review their influenza vaccination histories. If they were not vacci-
nated the previous fall or winter, they should consider influenza vaccination before
travel. Persons in the high-risk categories should be especially encouraged to receive
the most current vaccine. Persons at high risk who received the previous season’s
vaccine before travel should be revaccinated in the fall or winter with the current
vaccine.
PERSONS WHO SHOULD NOT BE VACCINATED
Inactivated influenza vaccine should not be administered to persons known to have
anaphylactic hypersensitivity to eggs or to other components of the influenza vaccine
without first consulting a physician (see Side Effects and Adverse Reactions). Use of
an antiviral agent (amantadine or rimantadine) is an option for prevention of influenza
A in such persons. However, persons who have a history of anaphylactic hypersensi-
tivity to vaccine components but who are also at higher risk for complications of
influenza may benefit from vaccine after appropriate allergy evaluation and desensiti-
zation. Specific information about vaccine components can be found in package
inserts for each manufacturer.
Adults with acute febrile illness usually should not be vaccinated until their
symptoms have abated. However, minor illnesses with or without fever should not
contraindicate the use of influenza vaccine, particularly among children with mild up-
per respiratory tract infection or allergic rhinitis.
SIDE EFFECTS AND ADVERSE REACTIONS
Because influenza vaccine contains only noninfectious viruses, it cannot cause
influenza. Respiratory disease after vaccination represents coincidental illness unre-
lated to influenza vaccination. The most frequent side effect of vaccination reported by
fewer than one-third of vaccinees is soreness at the vaccination site that lasts for up to
2 days. In addition, two types of systemic reactions have occurred:
• Fever, malaise, myalgia, and other systemic symptoms occur infrequently and
most often affect persons who have had no exposure to the influenza virus anti-
gens in the vaccine (e.g., young children). These reactions begin 6–12 hours after
vaccination and can persist for 1 or 2 days;
• Immediate—presumably allergic—reactions (e.g., hives, angioedema, allergic
asthma, and systemic anaphylaxis) occur rarely after influenza vaccination. These
reactions probably result from hypersensitivity to some vaccine component; the
majority of reactions are most likely related to residual egg protein. Although
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current influenza vaccines contain only a small quantity of egg protein, this protein
may induce immediate hypersensitivity reactions among persons with severe egg
allergy. Persons who have developed hives, have had swelling of the lips or tongue,
or have experienced acute respiratory distress or collapse after eating eggs should
consult a physician for appropriate evaluation to help determine if vaccine should
be administered. Persons with documented immunoglobulin E (IgE)-mediated hy-
persensitivity to eggs—including those who have had occupational asthma or
other allergic responses due to exposure to egg protein—may also be at increased
risk for reactions from influenza vaccine, and similar consultation should be consid-
ered. The protocol for influenza vaccination developed by Murphy and Strunk may
be considered for patients who have egg allergies and medical conditions that
place them at increased risk for influenza-associated complications (Murphy and
Strunk, 1985).
Hypersensitivity reactions to any vaccine component can occur. Although exposure
to vaccines containing thimerosal can lead to induction of hypersensitivity, most pa-
tients do not develop reactions to thimerosal when administered as a component of
vaccines even when patch or intradermal tests for thimerosal indicate hypersensitiv-
ity. When reported, hypersensitivity to thimerosal has usually consisted of local,
delayed-type hypersensitivity reactions.
Unlike the 1976–77 swine influenza vaccine, subsequent vaccines prepared from
other virus strains have not been associated clearly with an increased frequency of
Guillain-Barré syndrome (GBS). However, it is difficult to make a precise estimate of
risk for a rare condition such as GBS. In 1990–91, although there was no overall in-
crease in frequency of GBS among vaccine recipients, there may have been a small
increase in GBS cases in vaccinated persons 18–64 years of age, but not in those aged
≥65 years. In contrast to the swine influenza vaccine, the epidemiologic features of the
possible association of the 1990–91 vaccine with GBS were not as convincing. Even if
GBS were a true side effect, the very low estimated risk for GBS is less than that of
severe influenza that could be prevented by vaccine.
SIMULTANEOUS ADMINISTRATION OF OTHER VACCINES,
INCLUDING CHILDHOOD VACCINES
The target groups for influenza and pneumococcal vaccination overlap consider-
ably. Both vaccines can be administered at the same time at different sites without
increasing side effects. However, influenza vaccine must be administered each year,
whereas pneumococcal vaccine is not. Children at high risk for influenza-related com-
plications may receive influenza vaccine at the same time they receive other routine
vaccinations, including pertussis vaccine (DTP or DTaP). Because influenza vaccine
can cause fever when administered to young children, DTaP may be preferable in
those children ≥15 months of age who are receiving the fourth or fifth dose of pertus-
sis vaccine. DTaP is not licensed for the initial three-dose series of pertussis vaccine.
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TIMING OF INFLUENZA VACCINATION ACTIVITIES
Beginning each September (when vaccine for the upcoming influenza season
becomes available) persons at high risk who are seen by health-care providers for
routine care or as a result of hospitalization should be offered influenza vaccine. Op-
portunities to vaccinate persons at high risk for complications of influenza should not
be missed.
The optimal time for organized vaccination campaigns for persons in high-risk
groups is usually the period from mid-October through mid-November. In the United
States, influenza activity generally peaks between late December and early March.
High levels of influenza activity infrequently occur in the contiguous 48 states before
December. It is particularly important to avoid administering vaccine too far in ad-
vance of the influenza season in facilities such as nursing homes because antibody
levels may begin to decline within a few months of vaccination. Vaccination programs
can be undertaken as soon as current vaccine is available if regional influenza activity
is expected to begin earlier than December.
Children <9 years of age who have not been vaccinated previously should receive
two doses of vaccine at least 1 month apart to maximize the likelihood of a satisfactory
antibody response to all three vaccine antigens. The second dose should be adminis-
tered before December, if possible. Vaccine should be offered to both children and
adults up to and even after influenza virus activity is documented in a community.
STRATEGIES FOR IMPLEMENTING INFLUENZA
VACCINE RECOMMENDATIONS
Although rates of influenza vaccination have increased in recent years, surveys in-
dicate that less than half of the high-risk population receives influenza vaccine each
year. More effective strategies are needed for delivering vaccine to persons at high
risk and to their health-care providers and household contacts.
In general, successful vaccination programs have combined education for health-
care workers, publicity and education targeted toward potential recipients, a plan for
identifying (usually by medical-record review) persons at high risk, and efforts to re-
move administrative and financial barriers that prevent persons from receiving the
vaccine. Persons for whom influenza vaccine is recommended can be identified and
vaccinated in the settings described in the following paragraphs.
Outpatient Clinics and Physicians’ Offices
Staff in physicians’ offices, clinics, health-maintenance organizations, and em-
ployee health clinics should be instructed to identify and label the medical records of
patients who should receive vaccine. Vaccine should be offered during visits begin-
ning in September and throughout the influenza season. The offer of vaccine and its
receipt or refusal should be documented in the medical record. Patients among high-
risk groups who do not have regularly scheduled visits during the fall should be
reminded by mail or telephone of the need for vaccine. If possible, arrangements
should be made to provide vaccine with minimal waiting time and at the lowest pos-
sible cost.
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Facilities Providing Episodic or Acute Care
Health-care providers in these settings (e.g., emergency rooms and walk-in clinics)
should be familiar with influenza vaccine recommendations. They should offer vac-
cine to persons in high-risk groups or should provide written information on why,
where, and how to obtain the vaccine. Written information should be available in lan-
guage(s) appropriate for the population served by the facility.
Nursing Homes and Other Residential Long-Term–Care Facilities
Vaccination should be routinely provided to all residents of chronic-care facilities
with the concurrence of attending physicians rather than by obtaining individual vac-
cination orders for each patient. Consent for vaccination should be obtained from the
resident or a family member at the time of admission to the facility, and all residents
should be vaccinated at one time, immediately preceding the influenza season. Resi-
dents admitted during the winter months after completion of the vaccination program
should be vaccinated when they are admitted.
Acute-Care Hospitals
All persons ≥65 years of age and younger persons (including children) with high-
risk conditions who are hospitalized from September through March should be
offered and strongly encouraged to receive influenza vaccine before they are dis-
charged. Household members and others with whom they will have contact should
receive written information about why and where to obtain influenza vaccine.
Outpatient Facilities Providing Continuing Care to Patients at High Risk
All patients should be offered vaccine before the beginning of the influenza season.
Patients admitted to such programs (e.g., hemodialysis centers, hospital specialty-
care clinics, outpatient rehabilitation programs) during the winter months after the
earlier vaccination program has been conducted should be vaccinated at the time of
admission. Household members should receive written information regarding the
need for vaccination and the places to obtain influenza vaccine.
Visiting Nurses and Others Providing Home Care to Persons at High Risk
Nursing-care plans should identify patients in high-risk groups, and vaccine should
be provided in the home if necessary. Care givers and others in the household (includ-
ing children) should be referred for vaccination.
Facilities Providing Services to Persons ≥65 Years of Age
In these facilities (e.g., retirement communities and recreation centers), all unvacci-
nated residents/attendees should be offered vaccine on site before the influenza
season. Education/publicity programs should also be provided; these programs
should emphasize the need for influenza vaccine and provide specific information on
how, where, and when to obtain it.
Clinics and Others Providing Health Care for Travelers
Indications for influenza vaccination should be reviewed before travel, and vaccine
should be offered if appropriate (see Foreign Travelers).
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Health-Care Workers
Administrators of all health-care facilities should arrange for influenza vaccine to be
offered to all personnel before the influenza season. Personnel should be provided
with appropriate educational materials and strongly encouraged to receive vaccine.
Particular emphasis should be placed on vaccination of persons who care for
members of high-risk groups (e.g., staff of intensive-care units [including newborn
intensive-care units], staff of medical/surgical units, and employees of nursing homes
and chronic-care facilities). Using a mobile cart to take vaccine to hospital wards or
other work sites and making vaccine available during night and weekend work shifts
may enhance compliance, as may a follow-up campaign early in the course of com-
munity outbreak.
SOURCES OF INFORMATION ON
INFLUENZA-CONTROL PROGRAMS
Information regarding influenza surveillance is available through the CDC Voice In-
formation System (influenza update), telephone (404) 332-4551, or through the CDC
Information Service on the Public Health Network electronic bulletin board. From Oc-
tober through May, the information is updated at least every other week. In addition,
periodic updates about influenza are published in MMWR. State and local health de-
partments should also be consulted regarding availability of vaccine, access to
vaccination programs, and information about state or local influenza activity.
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